1
|
El Sabeh R, Bonnet M, Le Corf K, Lang K, Kfoury A, Badran B, Hussein N, Virard F, Treilleux I, Le Romancer M, Lebecque S, Manie S, Coste I, Renno T. A Gender-Dependent Molecular Switch of Inflammation via MyD88/Estrogen Receptor-Alpha Interaction. J Inflamm Res 2021; 14:2149-2156. [PMID: 34045885 PMCID: PMC8149287 DOI: 10.2147/jir.s306805] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 04/29/2021] [Indexed: 01/30/2023] Open
Abstract
Introduction Most Toll-like receptors and IL-1/IL-18 receptors activate a signaling cascade via the adaptor molecule MyD88, resulting in NF-κB activation and inflammatory cytokine and chemokine production. Females are less susceptible than males to inflammatory conditions, presumably due to protection by estrogen. The exact mechanism underlying this protection is unknown. Methods MCF7 cells expressing wild-type or mutated LXXLL motif were used to determine MyD88/estrogen receptor (ER)-a interaction by immunoprecipitation and cell activation by ELISA and luciferase reporter assay. IL-1b and/or E2 were used to activate MCF7 cells expressing normal or knocked down levels of PRMT1. Finally, in situ proximity ligation assay with anti-MyD88 and anti-methylated ER-a (methER-a) antibodies was used to evaluate MyD88/methylated ER-a interaction in THP1 cells and histological sections. Results We show that MyD88 interacts with a methylated, cytoplasmic form of estrogen receptor-alpha (methER-α). This interaction is required for NF-κB transcriptional activity and pro-inflammatory cytokine production, and is dissociated by estrogen. Importantly, we show a strong gender segregation in gametogenic reproductive organs, with MyD88/methER-α interactions found in testicular tissues and in ovarian tissues from menopausal women, but not in ovaries from women age 49 and less - suggesting a role for estrogen in disrupting this complex in situ. Discussion Collectively, our results indicate that the formation of MyD88/methER-α complexes during inflammatory signaling and their disruption by estrogen may represent a mechanism that contributes to gender bias in inflammatory responses.
Collapse
Affiliation(s)
- Rana El Sabeh
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,Université Libanaise, PRASE, Hadath, Lebanon
| | - Mélanie Bonnet
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Katy Le Corf
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Kevin Lang
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Alain Kfoury
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | | | | | - Francois Virard
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | | | - Muriel Le Romancer
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Serge Lebecque
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Serge Manie
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Isabelle Coste
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Toufic Renno
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| |
Collapse
|
2
|
Mazier W, Le Corf K, Martinez C, Tudela H, Kissi D, Kropp C, Coubard C, Soto M, Elustondo F, Rawadi G, Claus SP. A New Strain of Christensenella minuta as a Potential Biotherapy for Obesity and Associated Metabolic Diseases. Cells 2021; 10:823. [PMID: 33917566 PMCID: PMC8067450 DOI: 10.3390/cells10040823] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 03/20/2021] [Accepted: 04/02/2021] [Indexed: 12/11/2022] Open
Abstract
Obesity is associated with gut microbiota dysbiosis, characterized by a high Firmicutes/Bacteroidetes ratio. Gut-dwelling bacteria of the Christensenellaceae family have been proposed to act as keystones of the human gut ecosystem and to prevent adipogenesis. The objectives of the present study were to demonstrate the antiobesity potential of a new strain of Christensenella minuta in preclinical models and explore related mechanisms of action. The antiobesity potential of C. minuta DSM33407 was assessed in a diet-induced obesity mouse model. Changes in hepatic lipid metabolism were explored using targeted transcriptomics. Effects on gut microbiota were further assessed in a humanized Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model inoculated with obese fecal samples. Shotgun metagenomics was applied to study microbial community structures in both models. C. minuta DSM33407 protected from diet-induced obesity and regulated associated metabolic markers such as glycemia and leptin. It also regulated hepatic lipid metabolism through a strong inhibition of de novo lipogenesis and maintained gut epithelial integrity. In the humanized SHIME® model, these effects were associated with modulations of the intestinal microbiota characterized by a decreased Firmicutes/Bacteroidetes ratio. These data indicate that C. minuta DSM33407 is a convincing therapeutic candidate for the management of obesity and associated metabolic disorders.
Collapse
Affiliation(s)
- Wilfrid Mazier
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Katy Le Corf
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Ccori Martinez
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Héloïse Tudela
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Déborah Kissi
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Camille Kropp
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
- Micalis Institute, INRAE, AgroParisTech, University Paris-Saclay, 78350 Jouy-en-Josas, France
| | - Chrislain Coubard
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Marion Soto
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Frédéric Elustondo
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Georges Rawadi
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| | - Sandrine P. Claus
- Ysopia Bioscience, 17 place de la Bourse, 33076 Bordeaux, France; (W.M.); (K.L.C.); (C.M.); (H.T.); (D.K.); (C.K.); (C.C.); (M.S.); (F.E.); (G.R.)
| |
Collapse
|
3
|
de Laplanche E, Boudria A, Dacheux E, Vincent A, Gadot N, Assade F, Le Corf K, Leroy X, Mège Lechevallier F, Eymin B, Dalla Venezia N, Simonnet H. Low glucose microenvironment of normal kidney cells stabilizes a subset of messengers involved in angiogenesis. Physiol Rep 2015; 3:3/1/e12253. [PMID: 25602014 PMCID: PMC4387757 DOI: 10.14814/phy2.12253] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
As glucose is a mandatory nutrient for cell proliferation and renewal, it is suspected that glucose microenvironment is sensed by all cell types to regulate angiogenesis. Several glucose-sensing components have been partially described to respond to high glucose levels. However, little is known about the response to low glucose. Here, we used well-differentiated isolated normal rat renal tubules under normal oxygenation conditions to assess the angiogenic response to low glucose. In apparent paradox, but confirming observations made separately in other models, high glucose but also low glucose increased mRNA level of vascular endothelial growth factor A (VEGFA). A subset of mRNAs including hypoxia-inducible factor 1A (HIF1A), angiopoietin receptor (TIE-2), and VEGF receptor 2 (FLK1) were similarly glucose-sensitive and responded to low glucose by increased stability independently of HIF1A and HIF2A proteins. These results contribute to gain some insights as to how normal cells response to low glucose may play a role in the tumor microenvironment.
Collapse
Affiliation(s)
- Elodie de Laplanche
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| | - Asma Boudria
- Institut Albert Bonniot Equipe 2 Bases Moléculaires de la Progression des Cancers du Poumon, INSERM U823/Université Joseph Fourier, Grenoble, F-38000, France
| | - Estelle Dacheux
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| | - Anne Vincent
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| | - Nicolas Gadot
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Department of Pathology, Hôpital Edouard Herriot, Lyon, F-69000, France
| | - Fouzia Assade
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| | - Katy Le Corf
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| | - Xavier Leroy
- Institut de Pathologie, CHRU, Faculté de Médecine, Université de Lille, Lille, F-59000, France
| | | | - Béatrice Eymin
- Institut Albert Bonniot Equipe 2 Bases Moléculaires de la Progression des Cancers du Poumon, INSERM U823/Université Joseph Fourier, Grenoble, F-38000, France
| | - Nicole Dalla Venezia
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| | - Hélène Simonnet
- Université de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| |
Collapse
|
4
|
Kfoury A, Le Corf K, El Sabeh R, Journeaux A, Badran B, Hussein N, Lebecque S, Manié S, Renno T, Coste I. MyD88 in DNA repair and cancer cell resistance to genotoxic drugs. J Natl Cancer Inst 2013; 105:937-46. [PMID: 23766530 DOI: 10.1093/jnci/djt120] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND MyD88 is an adaptor molecule in Toll-like receptor and interleukin 1 receptor signaling implicated in tumorigenesis through proinflammatory mechanisms. We have recently reported that MyD88 also directly promotes optimal activation of the Ras/Erk pathway. Here we investigate MyD88 implication in the maintenance of the transformation of Ras-dependent tumors. METHODS RNA interference was used to inhibit MyD88 expression in the colon cancer cell lines HCT116 and LS513. Apoptosis, DNA damage, p53 function, ERCC1 levels, and Ras and inflammatory signaling pathways were analyzed. Using in vitro assays and xenotransplantation in nude mice (five per group), HCT116 tumor growth was assessed following MyD88 knockdown in presence or absence of chemotherapy. RESULTS MyD88 exerts antiapoptotic functions in colon cancer cells via the Ras/Erk, but not the NF-κB, pathway. MyD88 inhibition leads to defective ERCC1-dependent DNA repair and to accumulation of DNA damage, resulting in cancer cell death via p53. Furthermore, we show that knocking down MyD88 sensitizes cancer cells to genotoxic agents such as platinum salts in vitro and in vivo. Indeed, HCT116 tumor growth following treatment with a combination of suboptimal MyD88 inhibition and suboptimal doses of cisplatin (fold tumor increase = 5.4 ± 1.6) was statistically significantly reduced in comparison to treatment with doxycycline alone (12.4 ± 3.1) or with cisplatin alone (12.5 ± 2.6) (P = .005 for both, one-sided Student t test). CONCLUSIONS Collectively, these results indicate a novel and original link between inflammation, DNA repair, and cancer, and provide further rationale for MyD88 as a potential therapeutic target in Ras-dependent cancers, in the context of concomitant genotoxic chemotherapy.
Collapse
|
5
|
Coste I, Le Corf K, Kfoury A, Hmitou I, Druillennec S, Hainaut P, Eychene A, Lebecque S, Renno T. Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest 2010; 120:3663-7. [PMID: 20941850 DOI: 10.1172/jci42771] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Accumulating evidence points to inflammation as a promoter of carcinogenesis. MyD88 is an adaptor molecule in TLR and IL-1R signaling that was recently implicated in tumorigenesis through proinflammatory mechanisms. Here we have shown that MyD88 is also required in a cell-autonomous fashion for RAS-mediated carcinogenesis in mice in vivo and for MAPK activation and transformation in vitro. Mechanistically, MyD88 bound to the key MAPK, Erk, and prevented its inactivation by its phosphatase, MKP3, thereby amplifying the activation of the canonical RAS pathway. The relevance of this mechanism to human neoplasia was suggested by the finding that MyD88 was overexpressed and interacted with activated Erk in primary human cancer tissues. Collectively, these results show that in addition to its role in inflammation, MyD88 plays what we believe to be a crucial direct role in RAS signaling, cell-cycle control, and cell transformation.
Collapse
Affiliation(s)
- Isabelle Coste
- CNRS UMR5201, University of Lyon, Centre Léon Bérard, Lyon, France
| | | | | | | | | | | | | | | | | |
Collapse
|